Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
Authors
Keywords
Canagliflozin, Empagliflozin, GLP-1 receptor agonist, Heart failure, Liraglutide, Myocardial infarction, Renal decompensation, SGLT2 inhibitor, Stroke, Weight loss
Journal
Diabetes Therapy
Volume 9, Issue 3, Pages 919-926
Publisher
Springer Nature
Online
2018-04-05
DOI
10.1007/s13300-018-0420-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- (2018) Bernhard Ludvik et al. Lancet Diabetes & Endocrinology
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
- (2017) Konstantinos A. Toulis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological aspects of the safety of gliflozins
- (2017) Jean-Luc Faillie PHARMACOLOGICAL RESEARCH
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects
- (2016) Masashi Tanaka et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005–2011
- (2015) Ram D. Pathak et al. DIABETES CARE
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM
- (2015) Rachel M. Saroka et al. Endocrine Practice
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
- (2011) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
- (2011) M. Nagashima et al. DIABETOLOGIA
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
- (2010) Y. Hattori et al. DIABETOLOGIA
- The role of fat topology in the risk of disease
- (2009) Y Matsuzawa INTERNATIONAL JOURNAL OF OBESITY
- A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
- (2009) Hongbin Liu et al. JOURNAL OF ENDOCRINOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started